MHRA (UK)Original article
MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome
RegulatoryapprovedRedemploPositive
AI Analysis
Summary
The MHRA authorised plozasiran (Redemplo) on 19 October 2026 for adults with familial chylomicronaemia syndrome. The article excerpt does not name the sponsor or give further details.
Outcome Details
MHRA authorised plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome on 19 October 2026.
Importance:7/10
Sentiment:
0.70
MHRAUK approvalplozasiranRedemplofamilial chylomicronaemia syndromeFCSrare diseaseRNAi
Related Companies
Read the original article
Published by MHRA (UK) on October 19, 2026 3:42 PM